Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Deutsche Bank
German global banking and financial services company
-
Stifel
American investment bank
-
Nasdaq
American fully electronic stock exchange
Related events
- VSE Corporation was listed on the Nasdaq stock exchange and received analyst coverage and price targets from Morgan Stanley and TipRanks.
- Central Garden & Pet Company, which trades on the Nasdaq stock exchange, received rating upgrades and price target adjustments from various financial firms including Vanguard, JPMorgan, and Zacks.
- FirstCash traded on the Nasdaq stock exchange, filed required reports with the SEC, and saw its stock price affected by analyst ratings.
- First Seacoast Bancorp, trading on Nasdaq, saw BlackRock and other hedge funds acquire new stakes while Weiss Ratings upgraded its stock.
- VOR stock trades on the Nasdaq electronic exchange, and analyst reports are affecting company valuation.